Source:http://linkedlifedata.com/resource/pubmed/id/15585555
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2005-3-10
|
| pubmed:abstractText |
A distinctive feature of malignant adrenocortical neoplasms is decreased major histocompatibility complex (MHC) class II molecule expression. However, it is unknown whether there exists a restriction to certain MHC genotypes and whether this involves alterations of the Fas/Fas ligand system and thereby affects tissue homeostasis. Therefore, MHC class II phenotype and genotype and expression patterns of the Fas/Fas ligand system were investigated in 24 adrenocortical tumors (n(Adenomas) = 14, n(Carcinomas) = 10) and an adrenal cancer cell line (NCI-H295). No MHC class II antigen expression was detected in carcinomas. The DRB1*01 genotype was found in 54.5% of patients with carcinoma (P = 0.046). No prevalence of any genotype could be detected in patients with adenomas, which exhibited varying levels of antigen expression. Fas receptor expression was 75.0% in adenomas compared with 20.0% in carcinomas (P = 0.0196), whereas ligand expression was 37.7% in adenomas and reached almost 100% in the carcinomas investigated in this study (P = 0.0033). In summary, the DRB1*01 genotype may be correlated to a higher risk for malignancy. Additional studies on MHC class II genotype and phenotype and the altered Fas/Fas ligand system in adrenal neoplasms may help to identify mechanisms of immune escape and suggest new diagnostic approaches.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/FASLG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DRB1 Chains,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0021-972X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
90
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1768-74
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15585555-Adolescent,
pubmed-meshheading:15585555-Adrenal Cortex Neoplasms,
pubmed-meshheading:15585555-Adrenocortical Carcinoma,
pubmed-meshheading:15585555-Adult,
pubmed-meshheading:15585555-Aged,
pubmed-meshheading:15585555-Aged, 80 and over,
pubmed-meshheading:15585555-Antigens, CD95,
pubmed-meshheading:15585555-Child,
pubmed-meshheading:15585555-Child, Preschool,
pubmed-meshheading:15585555-Fas Ligand Protein,
pubmed-meshheading:15585555-Female,
pubmed-meshheading:15585555-Genetic Predisposition to Disease,
pubmed-meshheading:15585555-Genotype,
pubmed-meshheading:15585555-HLA-DR Antigens,
pubmed-meshheading:15585555-HLA-DRB1 Chains,
pubmed-meshheading:15585555-Humans,
pubmed-meshheading:15585555-Immunohistochemistry,
pubmed-meshheading:15585555-Male,
pubmed-meshheading:15585555-Membrane Glycoproteins,
pubmed-meshheading:15585555-Middle Aged,
pubmed-meshheading:15585555-Prevalence,
pubmed-meshheading:15585555-Risk Factors
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma.
|
| pubmed:affiliation |
Medical Department I, Faculty of Medicine Carl Gustav Carus, University of Technology Dresden, Fetscherstrasse 74, Dresden 01307, Germany. wolkersdoerfer@mk1.med.tu-dresden.de
|
| pubmed:publicationType |
Journal Article
|